PCI Pharma Services provides full manufacturing services for both investigational and commercial products including highly potent molecules requiring specialist handling.
Through the acquisition of Penn Pharma, PCI has significant experience in providing integrated drug development, clinical trial supply and manufacturing services of solid dose potent products to high standards of safety and quality.
Development and Manufacturing of Highly Potent Molecules – A Center of Excellence
The pharmaceutical landscape continues to evolve with more and more products in development being deemed potent. As the biological activity and specificity of Active Pharmaceutical Ingredients (API) increases, dosage strengths are decreasing which had led to this increase in more potent molecules. Significant investment in general contained resources resulted in PCI being awarded ISPE Facility of the Year 2014. Additional investment include both contained roller compaction and fully contained Xcelodose® 600S technology, further driving PCI’s market leading position.